Mitsubishi Tanabe Pharma provides Compound Library to Screening Program of Global Health Innovative Technology Fund

Osaka, Japan, May 22, 2015—Mitsubishi Tanabe Pharma Corporation (President and Representative Director: Masayuki Mitsuka) has endorsed the objectives of the Global Health Innovative Technology Fund (GHIT Fund) and has decided to participate in the GHIT Fund’s new candidate compound discovery program.

The GHIT Fund is a public-private partnership, originating in Japan, that advances the discovery of new drugs for infectious diseases that burden the developing world, such as malaria, tuberculosis, and neglected tropical diseases (NTDs). The GHIT Fund aims to bolster Japan’s international contribution to global health through new drug R&D capabilities that leverage the advanced scientific and technical knowledge of Japanese pharmaceutical companies and other institutions.

By participating in the new candidate compound discovery program, Mitsubishi Tanabe Pharma will be able to contribute to the treatment of infectious diseases that burden the developing world. Accordingly, the Company decided to provide its original pharmaceutical compound library (50,000 compounds). First, the Company, concluded a screening joint research agreement with Medicine for Malaria Venture (MMV), a screening institution that focuses on the discovery of anti-malaria drugs. The Company will provide its compound library to MMV through the GHIT Fund, and screening will target the discovery of new anti-malaria drug candidate compounds that overcome the problem of resistance to existing anti-malaria drugs. In the future, the Company plans to participate in other screening programs targeting the discovery of new drugs for other infectious diseases.

Through participation in the GHIT Fund, Mitsubishi Tanabe Pharma will contribute to the treatment of infectious diseases in the developing world.

(IF For Details, Contact the Following Section)
Corporate Communications Department
Tel +81-6-6205-5211